EUVIMEDEUVIMED entdecken
Klinische StudieMultizentrische Studie

The ‘Stop TPO‐RA in ITP Patients’ study: Clinical and immune modulatory effects of romiplostim tapering

Vivianne S Nelson iD, Sufia N Amini, Tanja Netelenbos, Marina S Kartachova, Roger E G Schutgens iD, Otto Visser, Peter E Westerweel, Jaap J Zwaginga, Suzanne Hofstede-van Egmond, Rick Kapur iD, Masja de Haas iD, Leendert Porcelijn iD und 1 weitere

British Journal of Haematology · 2025

DOI: 10.1111/bjh.20100 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Vivianne S Nelson und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Haga Teaching Hospital, The Hague, The Netherlands. Hauptthemen laut MEDLINE: Thrombopoietin, Purpura, Thrombocytopenic, Idiopathic, Receptors, Fc, Recombinant Fusion Proteins. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Amgen Nederland, Stichting Sanquin Bloedvoorziening.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sustained remissions off‐treatment (SROTs) after tapering of thrombopoietin receptor agonists (TPO‐RAs) have been reported in 15%–50% of patients with immune thrombocytopenia (ITP). The STIP (Stop TPO‐Receptor Agonist in ITP Patients) study is a prospective trial aimed to investigate the clinical effects of romiplostim tapering. Adult patients (22/40) with ITP ≥3 months received romiplostim for 1 year, were tapered and followed for 1 year. Anti‐platelet antibodies (APAs), TPO levels and indium‐111 platelet scintigraphy were assessed before, during and after romiplostim. Censored survival analysis showed that the probability of SROT at 1 year after tapering was 23.6% (95% confidence interval: 11.0%–50.5%). Patients with SROT had higher platelet levels on romiplostim (median: 332.5 vs. 84.5 × 10 9 /L) and lower romiplostim doses at the start of tapering (median: 1.0 vs. 4.5 μg/kg) compared to those with a non‐sustained response (NSR). APAs were detected in 8/25 patients at baseline, of which 5 showed a substantial decrease during romiplostim. The indium‐111 scan revealed an improved platelet survival at the start of tapering for 50% of patients with SROT (2/4, missing n = 1) versus none with an NSR (0/14, missing n = 3). Overall, the STIP study demonstrated a probability of SROT of 23.6% in a diverse and largely chronic group of adult patients with ITP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThrombopoietinPurpura, Thrombocytopenic, IdiopathicReceptors, FcRecombinant Fusion ProteinsReceptors, ThrombopoietinHumansFemaleMaleMiddle AgedAdultAgedProspective StudiesAutoantibodiesYoung Adult

Stichwörter der Autor:innen

anti‐platelet antibodiesimmune thrombocytopeniaindium‐111 platelet scintigraphythrombopoietin receptor agonist

Substanzen

romiplostimThrombopoietinReceptors, FcRecombinant Fusion ProteinsReceptors, ThrombopoietinAutoantibodies

Autor:innen und Institutionen

  • Department of Hematology, Haga Teaching Hospital, The Hague, The Netherlands.
  • Sanquin Blood Supply Foundation, Department Research, and Amsterdam UMC location University of Amsterdam, Landsteiner Laboratory, Amsterdam, The Netherlands.
  • Department of Hematology, Leiden University Medical Center (LUMC), Leiden, The Netherlands.
  • Department of Nuclear Medicine, Haga Teaching Hospital, The Hague, The Netherlands.
  • Center for Benign Hematology, Thrombosis and Hemostasis, Van Creveldkliniek, UMC Utrecht and University Utrecht, Utrecht, The Netherlands.
  • Department of Hematology, Isala, Zwolle, The Netherlands.

ORCID-Profile: Vivianne S Nelson, Roger E G Schutgens, Rick Kapur, Masja de Haas, Leendert Porcelijn

Förderung

  • Amgen Nederland
  • Stichting Sanquin Bloedvoorziening

Zitieren

APA

Nelson, V. S., Amini, S. N., Netelenbos, T., Kartachova, M. S., Schutgens, R. E. G., Visser, O., Westerweel, P. E., Zwaginga, J. J., Hofstede-van Egmond, S., Kapur, R., de Haas, M., Porcelijn, L., & Schipperus, M. R. (2025). The ‘Stop TPO‐RA in ITP Patients’ study: Clinical and immune modulatory effects of romiplostim tapering. British Journal of Haematology. https://doi.org/10.1111/bjh.20100

Vancouver

Nelson VS, Amini SN, Netelenbos T, Kartachova MS, Schutgens REG, Visser O, et al. The ‘Stop TPO‐RA in ITP Patients’ study: Clinical and immune modulatory effects of romiplostim tapering. British Journal of Haematology. 2025. doi:10.1111/bjh.20100

BibTeX
@article{Nelson2025,
  author = {Nelson, Vivianne S and Amini, Sufia N and Netelenbos, Tanja and Kartachova, Marina S and Schutgens, Roger E G and Visser, Otto and Westerweel, Peter E and Zwaginga, Jaap J and Hofstede-van Egmond, Suzanne and Kapur, Rick and de Haas, Masja and Porcelijn, Leendert and Schipperus, Martin R},
  title = {The ‘Stop TPO‐RA in ITP Patients’ study: Clinical and immune modulatory effects of romiplostim tapering},
  journal = {British Journal of Haematology},
  year = {2025},
  doi = {10.1111/bjh.20100}
}
Kostenlos starten →